Zobrazeno 1 - 10
of 280
pro vyhledávání: '"Christina M. Annunziata"'
Autor:
Brittney S. Harrington, Rahul Kamdar, Franklin Ning, Soumya Korrapati, Michael W. Caminear, Lidia F. Hernandez, Donna Butcher, Elijah F. Edmondson, Nadia Traficante, Joy Hendley, Australian Ovarian Cancer Study, Madeline Gough, Rebecca Rogers, Rohan Lourie, Jyoti Shetty, Bao Tran, Fathi Elloumi, Abdalla Abdelmaksoud, Madhu Lal Nag, Krystyna Mazan-Mamczarz, Carrie D. House, John D. Hooper, Christina M. Annunziata
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-22 (2023)
Abstract Background Epithelial ovarian cancer (EOC) is a global health burden, with the poorest five-year survival rate of the gynecological malignancies due to diagnosis at advanced stage and high recurrence rate. Recurrence in EOC is driven by the
Externí odkaz:
https://doaj.org/article/e245f4306b05418da579333a9dcc9d93
Autor:
Christopher B. Cole, Maria Pia Morelli, Massimo Fantini, Markku Miettinen, Patricia Fetsch, Cody Peer, William D. Figg, Tyler Yin, Nicole Houston, Ann McCoy, Stanley Lipkowitz, Alexandra Zimmer, Jung-min Lee, Miroslava Pavelova, Erin N. Villanueva, Kathryn Trewhitt, B. Brooke Solarz, Maria Fergusson, Sharon A. Mavroukakis, Anjum Zaki, Kwong Y. Tsang, Philip M. Arlen, Christina M. Annunziata
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-17 (2023)
Abstract Background NEO201 is a humanized IgG1 monoclonal antibody (mAb) generated against tumor-associated antigens from patients with colorectal cancer. NEO-201 binds to core 1 or extended core 1 O-glycans expressed by its target cells. Here, we pr
Externí odkaz:
https://doaj.org/article/156401e08d7b44f9b984a38a26842574
Autor:
Ramez N. Eskander, Kathleen N. Moore, Bradley J. Monk, Thomas J. Herzog, Christina M. Annunziata, David M. O’Malley, Robert L. Coleman
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
The definition of “platinum-resistant ovarian cancer” has evolved; it now also reflects cancers for which platinum treatment is no longer an option. Standard of care for platinum-resistant ovarian cancer is single-agent, non-platinum chemotherapy
Externí odkaz:
https://doaj.org/article/358e10443d3f428898b57cc9d3f7a136
Autor:
Elizabeth I. Harper, Tyvette S. Hilliard, Emma F. Sheedy, Preston Carey, Paul Wilkinson, Michael D. Siroky, Jing Yang, Elizabeth Agadi, Annemarie K. Leonard, Ethan Low, Yueying Liu, Arya Biragyn, Christina M. Annunziata, Mary Sharon Stack
Publikováno v:
Aging and Cancer, Vol 3, Iss 2, Pp 116-129 (2022)
Abstract Background Age is the most significant risk factor for ovarian cancer (OvCa), the deadliest gynecologic malignancy. Metastasizing OvCa cells adhere to the omentum, a peritoneal structure rich in collagen, adipocytes, and immune cells. Ultras
Externí odkaz:
https://doaj.org/article/58408a16a910405f8e3c9cfe215b7ce4
Autor:
Christopher B. Cole, Maria Pia Morelli, Massimo Fantini, Markku Miettinen, Patricia Fetsch, Cody Peer, William D. Figg, Tyler Yin, Nicole Houston, Ann McCoy, Stanley Lipkowitz, Alexandra Zimmer, Jung-min Lee, Miroslava Pavelova, Erin N. Villanueva, Kathryn Trewhitt, B. Brooke Solarz, Maria Fergusson, Sharon A. Mavroukakis, Anjum Zaki, Kwong Y. Tsang, Philip M. Arlen, Christina M. Annunziata
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/e0d1020045bf414299bb74825342f029
Publikováno v:
Cell Death Discovery, Vol 7, Iss 1, Pp 1-13 (2021)
Abstract Ovarian cancer is the most lethal gynecological cancer in the US. Standard treatment consists of surgery followed by chemotherapies relying on apoptotic tumor cell death. Most women with advanced stage disease will relapse, suggesting that t
Externí odkaz:
https://doaj.org/article/9c10067e1ca94c069a522c9a49e04d5d
Autor:
Rahul D. Kamdar, Brittney S. Harrington, Emma Attar, Soumya Korrapati, Jyoti Shetty, Yongmei Zhao, Bao Tran, Nathan Wong, Carrie D. House, Christina M. Annunziata
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 9, p 7826 (2023)
Epithelial ovarian cancer (EOC) remains the fifth leading cause of cancer-related death in women worldwide, partly due to the survival of chemoresistant, stem-like tumor-initiating cells (TICs) that promote disease relapse. We previously described a
Externí odkaz:
https://doaj.org/article/cb98457d4e81428ab556a97010f22902
Autor:
Yusuke Shibuya, Kei Kudo, Kristen P. Zeligs, David Anderson, Lidia Hernandez, Franklin Ning, Christopher B. Cole, Maria Fergusson, Noemi Kedei, John Lyons, Jason Taylor, Soumya Korrapati, Christina M. Annunziata
Publikováno v:
Cancers, Vol 15, Iss 4, p 1315 (2023)
The overexpression of inhibitor of apoptosis (IAP) proteins is strongly related to poor survival of women with ovarian cancer. Recurrent ovarian cancers resist apoptosis due to the dysregulation of IAP proteins. Mechanistically, Second Mitochondrial
Externí odkaz:
https://doaj.org/article/6c87cba16db0410abe4a35444f5e01ec
Autor:
Michael W. Caminear, Brittney S. Harrington, Rahul D. Kamdar, Michael J. Kruhlak, Christina M. Annunziata
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Epithelial ovarian cancer (EOC) is a global health burden and remains the fifth leading cause of cancer related death in women worldwide with the poorest five-year survival rate of the gynecological malignancies. EOC recurrence is considered to be dr
Externí odkaz:
https://doaj.org/article/14e1d4141a4547b7b2afe47a93cc6cab
Autor:
Kwong Y. Tsang, Massimo Fantini, Anjum Zaki, Sharon A. Mavroukakis, Maria Pia Morelli, Christina M. Annunziata, Philip M. Arlen
Publikováno v:
Cancers, Vol 14, Iss 20, p 4999 (2022)
Truncated O-glycans expressed in cancer cells support tumor progression, and they may serve as potential targets to improve the monitoring and treatment of cancers. Previously, we reported that NEO-201 binds to several tumors expressing tumor-associa
Externí odkaz:
https://doaj.org/article/df46147cb66742ffb91ef7bbc64933bf